Itraconazolum [Latin] en es it fr

Itraconazolum [Latin] Brand names, Itraconazolum [Latin] Analogs

Itraconazolum [Latin] Brand Names Mixture

  • No information avaliable

Itraconazolum [Latin] Chemical_Formula


Itraconazolum [Latin] RX_link

Itraconazolum [Latin] fda sheet

Itraconazolum_[Latin] FDA

Itraconazolum [Latin] msds (material safety sheet)

Itraconazolum_[Latin] MSDS

Itraconazolum [Latin] Synthesis Reference

No information avaliable

Itraconazolum [Latin] Molecular Weight

705.633 g/mol

Itraconazolum [Latin] Melting Point

166.2 oC

Itraconazolum [Latin] H2O Solubility


Itraconazolum [Latin] State


Itraconazolum [Latin] LogP


Itraconazolum [Latin] Dosage Forms

Capsules (100 mg); Liquid solution

Itraconazolum [Latin] Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Itraconazolum [Latin] Pharmacology

Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans.

Itraconazolum [Latin] Absorption

The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.

Itraconazolum [Latin] side effects and Toxicity

No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.

Itraconazolum [Latin] Patient Information

No information avaliable

Itraconazolum [Latin] Organisms Affected

Fungi, yeast and protozoans